Research Highlights Benefits of Aspirin, Monoclonal Antibody Use in Patients With Diabetes, COVID-19

September 10th 2021, 7:00pm


New research presented at the 5th Heart in Diabetes Conference highlights potential therapeutic options for patients with COVID-19 and diabetes.

FDA Grants Empagliflozin Breakthrough Therapy Designation in HFpEF

September 9th 2021, 3:00pm


The sodium glucose co-transporter 2 (SGLT2) inhibitor reduced cardiovascular death and hospitalization for heart failure by 21% in results presented August 27 during the recent European Society of Cardiology Congress.

Dr David McIntyre on Care Takeaways From COVID-19 for Pregnant Patients With Diabetes

September 7th 2021, 8:00pm


David McIntyre, MD, FRACP, describes lessons learned from the pandemic for ensuring appropriate continuation of care for pregnant patients with diabetes.

Increase in Both Type 1 and Type 2 Diabetes Seen Among US Youth Over 16-Year Period

September 2nd 2021, 9:03pm


Native American and Black youth aged 10 to 19 years had the highest incidence of type 2 diabetes overall.

Dr Deepak L. Bhatt Discusses SGLT Inhibitors’ Impact on Glycemic Control

August 30th 2021, 3:45pm


Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, outlines the role that sodium glucose co-transporter (SGLT) inhibitors play in patients with diabetes and diminished glomerular filtration rates.

USPSTF Lowers Recommended T2D, Prediabetes Screening Age to 35 Years

August 26th 2021, 4:00pm


The United States Preventive Services Task Force (USPSTF) lowered its recommended screening age for type 2 diabetes and prediabetes from 40 to 35 years among overweight and obese individuals.

Cost-effectiveness of Intensification With SGLT2 Inhibitors for Type 2 Diabetes

August 25th 2021, 4:00pm


Adding a sodium-glucose co-transporter 2 (SGLT2) inhibitor dominated switching to a glucagon-like peptide 1 receptor agonist over the lifetimes of patients with type 2 diabetes not at glycated hemoglobin A1c target after treatment with metformin plus a dipeptidyl peptidase-4 inhibitor.

FDA Approves Empagliflozin to Treat HFrEF Regardless of T2D Status

August 19th 2021, 5:15pm


The FDA has approved empagliflozin (Jardiance) for adults with heart failure with reduced ejection fraction, regardless of type 2 diabetes status.

Jump in US Gestational Diabetes Rates Seen Across All Racial, Age Groups

August 17th 2021, 3:30pm


An analysis of gestational diabetes trends in the United States revealed increases across all age and racial subgroups over the past decade.

Catlin Dennis Outlines Lessons Learned From COVID-19 for Vulnerable Youth With Diabetes

August 16th 2021, 3:26pm


Catlin Dennis, MPH, explains the importance of securing internet and technology access among vulnerable youth with diabetes.